Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients PIK3CA mutációs vastagbélrákban szenvedő betegek kiegészítő aszpirin kezelése

Update Il y a 4 ans
Reference: EUCTR2015-001482-57

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The objective of the trial is to demonstrate a statistically significant and clinically relevant disease free survival benefit in stage II and III PIK3CA mutated colon cancer patients taking daily adjuvant aspirin for 3 years.


Inclusion criteria

  • PIK3CA mutated colon cancer

Links